Nutex Health (NUTX) is back on investors’ radar after Q1 2026 results showed net income more than doubling year over year, stronger EPS, and continued hospital expansion plans supported by its existing arbitration driven model.

That earnings surprise and expansion pipeline have coincided with a sharp rebound in the shares, with a 1 day share price return of 17.1%, 7 day share price return of 28.9% and 30 day share price return of 41.8%. The 1 year total shareholder return of 21.8% sits alongside a 3 year total shareholder return of about 7x, suggesting momentum has recently shifted after earlier weakness.

If Nutex Health’s rebound has you rethinking where growth in healthcare might come from next, it could be worth scanning for other names riding similar trends through the 33 healthcare AI stocks

With Nutex Health’s earnings jump, active buybacks, and new hospitals on the way, the key question now is simple: is the share price still playing catch up, or is the market already pricing in the next leg of growth?

Most Popular Narrative: 15.7% Undervalued

The current Nutex Health share price of $139.57 sits below the narrative fair value of $165.64, which positions the story around a discounted entry point.

Intrinsic value: Some analyses show the stock is deeply undervalued based on its intrinsic value compared to its current market price, with one source estimating it to be undervalued by over 100%.

According to mstock, this narrative leans heavily on strong earnings growth, expanding margins, and a valuation multiple more often associated with much larger healthcare names. Want to see which specific growth and profitability assumptions sit behind that $165.64 figure and how they shape the case for Nutex Health?

Result: Fair Value of $165.64 (UNDERVALUED)

However, investors still need to watch Nutex Health’s legal and regulatory exposure around billing, as well as any renewed reporting or governance slip ups that could quickly weaken this bullish narrative.

Another View: Our DCF Flags Caution

While the popular narrative sees Nutex Health as 15.7% undervalued at $165.64, the Simply Wall St DCF model points in the opposite direction. On this cash flow based view, the current $139.57 share price sits well above an estimated value of $16.54, which suggests Nutex could be significantly overvalued instead. For investors, that gap raises a simple question: which story feels more realistic for the next few years?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Nutex Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

After all this, do you feel the story here leans more toward risk or reward, and are you ready to form your own view quickly using the 4 key rewards and 3 important warning signs

Looking for more investment ideas?

If Nutex Health has sharpened your focus, do not stop here. Lining up a few fresh ideas now can make your next move feel far more deliberate.

• Spot resilient cash generators first by screening for companies in the solid balance sheet and fundamentals stocks screener (44 results).
• Hunt for potential mispricings before the crowd by scanning the 51 high quality undervalued stocks.
• Lock in income focused ideas by reviewing companies in the 13 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.